Background: The development of liver fibrosis is the key stage toward a number of mortal complications of liver diseases, including cirrhosis and hepatocellular carcinoma. Canonical Wnt pathway is crucial in diverse biological processes and mediates the progression and regression of liver fibrosis. As a potent Wnt pathway agonist, roof plate-specific spondin-1 (R-spondin1) protein's role in the hepatic fibrosis has not been well elucidated. The purpose of this study was to investigate whether R-spondin1 contributed to hepatic stellate cells (HSC) activation, the key event in liver fibrogenesis.
Materials And Methods: Tissue microarrays of human fibrotic liver samples, hepatocellular carcinoma samples, and normal hepatic tissue samples were constructed and immunostained for R-spondin1. Protein expression and transcriptional level of freshly isolated mice HSC were analyzed by Western blot assay and real-time polymerase chain reaction, respectively. Exogenous stimulation with recombinant R-spondin1 and Dickkopf-1 was performed to investigate the functionality. Nuclear β-catenin level and T-cell specific transcription factor activity were analyzed, and HSC proliferation was tested by Methyl-Thiazol-Tetrazolium bromide assay.
Results: Overexpression of R-spondin1 was observed in both fibrotic liver tissues and culture-activated HSC. Coculture with recombinant R-spondin1 induced a dose-dependent increase in both the transcription factor activity and the protein level of α-smooth muscle actin, collagen I, and nuclear β-catenin. Additionally, Dickkopf-1 repressed R-spondin1's effect on HSC.
Conclusions: These findings suggested that R-spondin1 might argument liver fibrogenesis by enhancing the canonical Wnt pathway.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jss.2014.08.009 | DOI Listing |
Int J Pharm
January 2025
Department of Physics, Kharazmi University, Tehran, Iran; Endocrinology and Metabolism Research Center, Tehran University of Medical Sciences, Tehran, Iran. Electronic address:
Colorectal cancer (CRC) remains a significant public health concern, emphasizing the need for innovative therapeutic strategies to improve patient outcomes. This study aimed to develop a highly efficient nanocarrier for targeted drug delivery, enhancing drug efficacy while minimizing concentrations and limiting adverse effects. We synthesized protein-based β-lactoglobulin (βlg) nanoparticles (NPs), loaded with 5-fluorouracil (5-FU) and sodium butyrate (NaB), and further functionalized with folic acid (FA) for specific targeting of folate receptor-positive CRC cells.
View Article and Find Full Text PDFFront Oncol
January 2025
Department of Obstetrics and Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
[This corrects the article DOI: 10.3389/fonc.2022.
View Article and Find Full Text PDFBone Res
January 2025
Institute of Life Course and Medical Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK.
Low-density lipoprotein receptor-related protein 1 (LRP1) is a multifunctional endocytic receptor whose dysfunction is linked to developmental dysplasia of the hip, osteoporosis and osteoarthritis. Our work addresses the critical question of how these skeletal pathologies emerge. Here, we show the abundant expression of LRP1 in skeletal progenitor cells at mouse embryonic stage E10.
View Article and Find Full Text PDFBioorg Chem
January 2025
Department of Zoology, Aligarh Muslim University, Aligarh 202002, India. Electronic address:
Small molecules are emerging as potential candidates for treating osteoporosis by activating canonical Wnt signaling. These candidates work either by inhibiting DKK-1, sclerostin, SFRP-1, NOTUM, and S1P lyase or by preventing β-catenin degradation through inhibition of GSK-3β, or by targeting Dvl-CXXC5 and axin/β-catenin interactions. While many of these anti-osteoporotic small molecules are in preclinical development, the paucity of FDA-approved small molecules, or promising candidates, that have progressed to clinical trials for treating bone disorders through this mechanism poses a challenge.
View Article and Find Full Text PDFTransl Oncol
January 2025
Department of Gastroenterology, Changzheng Hospital, Naval Medical University, 415 Fengyang Road, Shanghai 200003, China. Electronic address:
Previous studies have demonstrated that intrahepatic cholangiocarcinoma (ICC) may derive from transdifferentiation of hepatocytes, so transforming ICC cells into hepatocytes could be a potential strategy for treating ICC. Hepatocyte nuclear factor 4α (HNF4α), a master transcription factor in the liver, has been demonstrated to induce the differentiation of hepatocellular carcinoma, while its effects on ICC remains unclear. Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor, is a novel targeted drug for ICC patients.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!